Sotatercept significantly increased the distance that cardiovascular patients could walk over a 24-week period. Patients in the trial also saw improvements in eight of the nine outcome measures for cardiovascular patients set by the World Health Organization.
The trial also found sotatercept reduced the risk of clinical worsening or death by 84 percent compared to a placebo, according to a March 6 press release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
